Researchers have discovered a key reason some cancer patients relapse after receiving chimeric antigen receptor T-cell ...

Dr Dinesh Pendharkar highlights how CAR T–cell therapy is reshaping cancer care in India by equipping the immune system with ...

The Food and Drug Administration has announced new guidelines that will make CAR T-cell therapy more accessible to cancer ...

Olalekan O. Oluwole discusses how CAR T-cell therapy is used to treat high-risk hematologic malignancies like lymphoma and ...

Explore the latest advancements in immunotherapies for T-cell lymphoma, addressing unique challenges and promising new treatment options.

Mayo Clinic researchers say they have identified why some cancer patients relapse after receiving CAR-T cell therapy. The study, published in Molecular Cancer, reveals that the engineered immune cells ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, explains that sequencing novel multiple myeloma therapies with CAR T-cell therapy is generally prioritized first for eligible patients, ...

Cartesian's mRNA-based cell therapy offers a novel, outpatient approach for autoimmune diseases. Promising results, but Phase ...

The FDA has loosened safety restrictions for six CAR T-cell immunotherapies, used in treating a number of blood cancers.

Peter M. Voorhees, MD, shares key insights from the 2025 American Society of Clinical Oncology Annual Meeting, specifically in the multiple myeloma space.

The discovery may explain why cutting edge CAR T-cell therapy has managed to revolutionized treatment for blood cancer but can struggle against solid tumors.